Table 3 Changes in proportions of subsets and surface markers of B cells, natural killer cells and monocytes during tocilizumab treatment

B cells/lymphocytes

3.2 (2 to 5.1)

4.1 (3.1 to 5.2)

4.1 (3.1 to 5.2)

CD80⁺ B cells/B cells

26.9 (13.5 to 32)

19.3 (12.4 to 26.3)

19.3 (13.2 to 21.4)

CD86⁺ B cells/B cells

42.5 (36.5 to 47.6)

34 (29.2 to 38.1)

36.7 (32.1 to 41.9)

HLA-DR⁺ B cells/B cells

99.6 (99 to 99.8)

99.4 (98.8 to 99.8)

99.5 (99.3 to 99.8)

Naïve B cells/B cells

52 (43.1 to 60.3)

62.7 (52.7 to 68.2)

66.7 (57.6 to 74.6)

Memory B cells/B cells

48 (39.7 to 56.9)

37.3 (31.8 to 47.3)

33.3 (25.4 to 42.4)

NK cells/lymphocytes

24.1 (20.0 to 27.5)

25.8 (21.2 to 30.5)

24.5 (20.9 to 29.5)

CD80⁺CD14⁺ monocytes/CD14⁺ monocytes

0.2 (0.1 to 0.3)

0.2 (0.1 to 0.3)

0.2 (0.1 to 0.3)

CD86⁺CD14⁺ monocytes/CD14⁺ monocytes

99.6 (99.2 to 99.9)

99.7 (99.3 to 99.9)

99.8 (99.6 to 99.9)

HLA-DR⁺CD14⁺ monocytes/CD14⁺ monocytes

99.5 (89.3 to 99.8)

98.2 (89.7 to 99.6)

94.6 (86 to 95.8)

CD69⁺CD14⁺ monocytes/CD14⁺ monocytes

66.7 (60.6 to 74.8)

48.3 (35.8 to 70.1)

34 (26.2 to 56.9)

CD16⁺CD14⁺ monocytes/CD14⁺ monocytes

16 (10.3 to 20.9)

8.6 (4.5 to 12.6)

8.1 (3.8 to 12.9)

CD16⁻CD14⁺ monocytes/CD14⁺ monocytes

84 (79.1 to 89.7)

91.4 (87.4 to 95.5)

91.9 (87.1 to 96.2)